Yamauchi et al. investigate the effects of treatment with the kinase inhibitor lenvatinib on immune parameters via multi-omics analysis of liver cancer and peripheral blood samples. Immune signatures associated with T-cell functions and interferon response are enriched during early treatment, while immunoinhibitory signatures are downregulated.
- Masami Yamauchi
- Atsushi Ono
- Shiro Oka
